Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors. The capital raise reflects significant operational momentum driven by Pathos’s proprietary AI platform, Foundry. Over the past se